Compare Biogen Inc (BIIB) vs Royal Caribbean Cruises Ltd (RCL) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Biogen Inc vs Royal Caribbean Cruises Ltd — how do they compare? Biogen Inc trades at $204.1 (market cap $30.13B), while Royal Caribbean Cruises Ltd trades at $307.2 (market cap $82.15B). The key difference: Royal Caribbean Cruises Ltd is far larger — about 2.7× Biogen Inc's market cap, and Royal Caribbean Cruises Ltd pays a 1.63% dividend while Biogen Inc pays none. Which is the better fit depends on your goals.
| BIIB | RCL | |
|---|---|---|
Market Cap | $30.13B | $82.15B |
Sector | Health | Consumer Cyclical |
52-Week High | $216.63 | $365.84 |
52-Week Low | $128.93 | $246.71 |
Enterprise Value | $37.20B | $104.79B |
Dividend Yield | — | 1.63% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Biogen (BIIB) trades at $208.85, up 0.83% with bullish technical signals and strong institutional support. The company has delivered three consecutive earnings beats, with Q2 2026 EPS of $3.60 exceeding estimates by 22%. Recent acquisition of RayThera and raised 2026 guidance demonstrate strategic growth initiatives. Valuation metrics show a P/E of 36.21 and P/S of 3.01, while maintaining solid profitability with 73.99% gross margins.
Biogen presents a compelling investment case with strong earnings momentum and strategic acquisitions driving growth. However, investors face risks from declining legacy MS drug sales and net income margin compression from 16.86% in 2024 to 8.32% projected for 2026. The stock offers 12% upside to consensus price target of $234.47, supported by 62.5% analyst buy ratings.
Royal Caribbean (RCL) trades at $307.87, showing minimal daily movement (-0.04%) with a bullish technical signal. The company demonstrates strong fundamental momentum with Q2 2026 EPS beating expectations at $4.21 versus $3.98, and robust profitability metrics including 23.54% net income margin and 45.33% ROE. Recent news highlights strong demand trends and the pricing of $1.25 billion in senior notes to support growth initiatives.
RCL presents a compelling growth story with record bookings and improved financial health, though elevated valuation ratios (P/E 18.97, P/S 4.46) and geopolitical risks in Europe warrant caution. Analyst consensus remains positive with a $343.09 price target, suggesting approximately 11% upside potential from current levels.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Biogen Inc
Biogen and Idec merged in 2003, combining forces to market Biogen's multiple sclerosis drug Avonex and Idec's cancer drug Rituxan. Today, Rituxan and next-generation antibody Gazyva are marketed via a collaboration with Roche. Biogen also markets novel MS drugs Plegridy, Tysabri, Tecfidera, and Vumerity. In Japan, Biogen's MS portfolio is co-promoted by Eisai. Hemophilia therapies Eloctate and Alprolix (partnered with SOBI) were spun off as part of Bioverativ in 2017. Biogen has several drug candidates in phase 3 trials in neurology and neurodegenerative diseases and has launched Spinraza with partner Ionis. Aduhelm was approved as the firm's first Alzheimer's disease therapy in June 2021.
Read more on BIIB →About Royal Caribbean Cruises Ltd
Royal Caribbean is the world's second-largest cruise company, operating 64 ships across five global and partner brands in the cruise vacation industry, with 10 more ships on order. Brands the company operates include Royal Caribbean International, Celebrity Cruises, and Silversea. The company also has a 50% investment in a joint venture that operates TUI Cruises and Hapag-Lloyd Cruises, allowing it to compete on the basis of innovation, quality of ships and service, variety of itineraries, choice of destinations, and price. The company completed the divestiture of its Azamara brand in the first quarter of 2021.
Read more on RCL →
